|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Debt Securities, available-for-sale, net of allowance for credit losses of $24 and $11 at June 30, 2026 and December 31, 2025, respectively (amortized cost: 2026 $55,815; 2025 $50,491) | ||||||||||||||||||||
| Debt Securities, at fair value under fair value option | ||||||||||||||||||||
| Debt Securities, trading, at fair value | ||||||||||||||||||||
| Equity securities, at fair value | ||||||||||||||||||||
| Mortgage loans, net of allowance for credit losses of $148 and $165 at September 30, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Mortgage loans, net of allowance for credit losses of $176 and $133 at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Mortgage loans, at fair value under fair value option | ||||||||||||||||||||
| Total mortgage loans, net of allowance for credit losses of $148 and $165 at September 30, 2024 and December 31, 2023, respectively | ||||||||||||||||||||
| Policy loans (including $3,617 and $3,537 at fair value under the fair value option at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Freestanding derivative instruments | ||||||||||||||||||||
| Other invested assets | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Deferred acquisition costs | ||||||||||||||||||||
| Reinsurance recoverable, net of allowance for credit losses of $31 and $30 at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Reinsurance recoverable on market risk benefits, at fair value | ||||||||||||||||||||
| Market risk benefit assets, at fair value | ||||||||||||||||||||
| Deferred income taxes, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Separate account assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Reserves for future policy benefits and claims payable | ||||||||||||||||||||
| Other contract holder funds | ||||||||||||||||||||
| Account values with crediting rates | ||||||||||||||||||||
| Market risk benefit liabilities, at fair value | ||||||||||||||||||||
| Funds withheld payable under reinsurance treaties (including $3,806 and $3,723 at fair value under the fair value option at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Short-term debt | ||||||||||||||||||||
| Debt | ||||||||||||||||||||
| Securities lending payable | ||||||||||||||||||||
| Repurchase agreements and securities lending payable | ||||||||||||||||||||
| Collateral payable for derivative instruments | ||||||||||||||||||||
| Freestanding derivative instruments | ||||||||||||||||||||
| Freestanding derivatives | ||||||||||||||||||||
| Total freestanding derivative instruments | ||||||||||||||||||||
| Other Liabilities | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Separate account liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| Series A non-cumulative preferred stock and additional paid in capital, $1.00 par value per share: 24,000 shares authorized; 22,000 shares issued and outstanding at June 30, 2026 and December 31, 2025; liquidation preference $25,000 per share (see Note 19) | ||||||||||||||||||||
| Common stock; 1,000,000,000 shares authorized, $0.01 par value per share and 68,185,286 and 66,825,632 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively (see Note 19) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock, at cost; 26,303,029 and 27,662,683 shares at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Accumulated other comprehensive income (loss), net of tax expense (benefit) of $(286) and $(377) at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
